Skip to main content
. 2022 Jan 20;14:83–93. doi: 10.2147/CLEP.S341048

Table 2.

Characteristics of Exposed and Unexposed Controls at Index Date: Asthma Patients Aged 20–59 Years in CPRD GOLD 1995–2015

Exposed (n=2909) Unexposed (n=1763) OR (95% CI)
Age at Index (years)
20–29 176 (6.1%) 168 (9.5%) 1.0 (reference)
30–39 392 (13.5%) 436 (24.7%) 0.9 (0.7–1.1)
40–49 665 (22.9%) 471 (26.7%) 1.3 (1.1–1.7)
50–59 1676 (57.6%) 688 (39.0%) 2.3 (1.8–2.9)
Sex
Male 1213 (41.7%) 719 (40.8%) 1.0 (reference)
Female 1696 (58.3%) 1044 (59.2%) 1.0 (0.9–1.1)
BMI (kg/m2)
<18 30 (1.0%) 18 (1.0%) 1.1 (0.6–1.9)
18–24 928 (31.9%) 598 (33.9%) 1.0 (reference)
25–30 859 (29.5%) 498 (28.3%) 1.1 (1.0–1.3)
>30 852 (29.3%) 432 (24.5%) 1.3 (1.1–1.5)
Unknown 240 (8.3%) 217 (12.3%) 0.7 (0.6–0.9)
Smoking Status
Non-smoker 1351 (46.4%) 868 (49.2) 1.0 (reference)
Current smoker 596 (20.5%) 393 (22.3) 1.0 (0.8–1.1)
Past-smoker 898 (30.9%) 444 (25.2) 1.3 (1.1–1.5)
Unknown 64 (2.2%) 58 (3.3) 0.7 (0.5–1.0)
Comorbidities
Phlebitis 51 (1.8%) 15 (0.9%) 2.1 (1.2–3.7)
Drug abuse 10 (0.3%) 9 (0.5%) 0.7 (0.3–1.7)
Hypertension 611 (21.0%) 231 (13.1%) 1.8 (1.5–2.1)
Diabetes 138 (4.7%) 51 (2.9%) 1.7 (1.2–2.3)
Hyperlipidemia 345 (11.9%) 150 (8.5%) 1.4 (1.1–1.8)
Alcohol abuse 33 (1.1%) 15 (0.9%) 1.3 (0.7–2.5)
COPD 293 (10.1%) 34 (1.9) 5.7 (4.0–8.2)
Epilepsy 12 (0.4%) NR 2.4 (0.7–8.6)
HRT or OCP Use
<90 days before index 253 (8.7%) 129 (7.3%) 1.2 (1.0–1.5)

Notes: Categorical variables are presented as N (%). Exposed = glucocorticoid use less than 1 year prior to the index date; Unexposed = glucocorticoid use 1 year or more prior to the index date; Current use = glucocorticoid use that continued to the index date; Recent use = glucocorticoid use less than 180 days prior to the index date; Past use= glucocorticoid use 180 days-less than 1 year prior to the index date.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HRT, hormone replacement therapy; OCP, oral contraceptive pills; NA, not applicable; NR, not reportable.